Sanctuary Advisors LLC Buys Shares of 19,611 Halozyme Therapeutics, Inc. $HALO

Key Points

• Sanctuary Advisors acquired 19,611 Halozyme shares worth approximately $1.535 million in the second quarter, while institutional investors collectively own 97.79% of the company.
• Analysts remain broadly positive, with nine Buy ratings, three Holds and one Sell; Halozyme’s average rating is “Moderate Buy” with a $91.20 average price target, though some firms raised targets as high as $115.
• Halozyme reported strong quarterly results, earning $2.28 per share versus the $1.79 estimate and generating $481 million in revenue, up 47.7% year over year. Shares opened at $107.06, near their 52-week high of $109.66, while insiders sold $5.23 million of stock over the past 90 days.

Sanctuary Advisors LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 19,611 shares of the biopharmaceutical company's stock, valued at approximately $1,535,000.

Other institutional investors have also recently made changes to their positions in the company. Meiji Yasuda Asset Management Co Ltd. acquired a new position in Halozyme Therapeutics in the second quarter valued at approximately $212,000. Elevation Point Wealth Partners LLC purchased a new stake in Halozyme Therapeutics in the second quarter valued at $264,000. Commerce Bank purchased a new stake in Halozyme Therapeutics in the second quarter valued at $1,347,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $59,000. Finally, Quantbot Technologies LP acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $30,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insiders Place Their Bets

In related news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director directly owned 40,418 shares of the company's stock, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 64,103 shares of company stock worth $5,226,496 over the last 90 days. Corporate insiders own 2.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HALO. UBS Group restated a "buy" rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Leerink Partners upgraded shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an "equal weight" rating in a report on Friday, August 7th. Citigroup reaffirmed a "market outperform" rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Finally, HC Wainwright lifted their target price on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a "buy" rating in a report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $91.20.

Halozyme Therapeutics Trading Down 2.1%

NASDAQ HALO opened at $107.06 on Thursday. The firm has a 50 day simple moving average of $85.50 and a 200-day simple moving average of $74.39. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $109.66. The firm has a market cap of $12.15 billion, a price-to-earnings ratio of 31.96, a PEG ratio of 0.44 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to analysts' expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business's quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source